Anti-CD19 CAR T-cell therapy (Sheba Medical Center)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameAnti-CD19 CAR T-cell therapy (Sheba Medical Center)
Drug Alias NameSHB-02-CD19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Myeloid, Acute +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSheba Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesSheba Medical Center
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Myeloid, Acute +[5] 
Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A